Id |
Subject |
Object |
Predicate |
Lexical cue |
T448 |
0-372 |
Sentence |
denotes |
Tocilizumab is a recombinant humanized monoclonal antibody inhibiting membrane-bound and soluble IL-6 receptors [68] and is currently approved for the treatment of patients with rheumatoid arthritis, giant-cell arteritis, juvenile idiopathic arthritis and patients with chimeric antigen receptor T-cell–induced severe or life-threatening cytokine release syndrome [68,69]. |
T449 |
373-528 |
Sentence |
denotes |
In this regard, tocilizumab may help mitigate the cytokine release syndrome by decreasing cytokine concentrations and acute-phase reactant production [70]. |
T450 |
529-648 |
Sentence |
denotes |
In a recent preprint paper, Xu et al. [71] reported their experience of treating 21 COVID-19 patients with tocilizumab. |
T451 |
649-1039 |
Sentence |
denotes |
In their still-to-be-peer-reviewed case series, the following were observed after tocilizumab administration: (a) reduction in body temperature (21/21, 100%); (b) improved blood oxygenation (15/21, 71.4%); (c) normalization of lymphocyte count (10/17, 58.8%); (d) normalization of C-reactive protein (16/19, 82.4%); and (c) resolution of abnormalities on computed tomography (19/21, 90.5%). |
T452 |
1040-1166 |
Sentence |
denotes |
Interestingly, no adverse reactions were observed after tocilizumab administration, but long-term follow-up was not available. |
T453 |
1167-1325 |
Sentence |
denotes |
Tocilizumab has been deemed by Chinese National Health Commission to be a possible treatment option for patients with severe COVID-19 with elevated IL-6 [72]. |
T454 |
1326-1508 |
Sentence |
denotes |
The recommended dose is 4 to 8 mg/kg or 400 mg standard dose provided intravenously once, with the option to repeat a dose after 8 to 12 hours (not to exceed a total dose of 800 mg). |
T455 |
1509-1706 |
Sentence |
denotes |
However, it should be noted that the optimal time for administering tocilizumab has not yet been fully elucidated; nor is there a clear IL-6 threshold associated with progression to severe disease. |
T456 |
1707-1849 |
Sentence |
denotes |
At the time of writing, there are at least eight ongoing RCT evaluating the efficacy and safety of tocilizumab in COVID-19 patients (Table 2). |